Prof. Dr Mohamed-Dahmani Fathallah

1 - Profile

Professor of Biotechnology, Higher Education Manager, Certified Innovation Strategist & Expert in Biotech Management with:  30 years of International experience In Academia : Teaching, Scientific Research & Development ,Training, Supervision and higher education strategy and management (Curricula design, Department chairing, Deanship)  25 years of Biopharmaceutical products & Bio Services Development, Production, Regulations and Market Analysis.  20 years of International Biotech high Management, Transfer of technology, Strategy Setting, Consultancy, Business Assessment.

2 - Personal Data

Nationality : Tunisian City of Residence: Manama, Bahrain Date of Birth : 03-02-1957 Contact Number: (973) 17239621 Place of Birth : Kairouan-Tunisia E-Mail address : [email protected] [email protected]

3.-Current position: Arabian Gulf University, Manama Bahrain Since September 2009:  Professor of Biotechnology.  Dean College of Graduate Studies.  Chairman of the Biotechnology PhD Program.  Chairman of the College of Graduate Studies Council.  Head of the College of Graduate Studies Scientific Research Committee.  Head of AGU Promotion Committee.  Editor in Chief: Arab Gulf Journal of Scientific Research.  Member of the Arabian Gulf University Strategy Steering Committee

Other Activities:  UN expert in Science, Technologies & Innovation

 Senior Technology Transfer, International Consultant.

 Member of the National Board for Scientific Research at 1 Bahrain Ministry of Education

Page

 Member of the National Board for High Education accreditation at Bahrain Ministry of Education.  Vice president of the Clinical Trials Committee at the Bahraini National Health Regulations Authority. “NAHRA”  Member of the Jury of King Faisal International Prize for Sciences  Member of the International Board of the Arab-German Academy of Sciences  Member of the Al Fiqh Al Islamy International Academy-Jeddah-KSA  President and Founder Harvard Alumni in Tunisia.  Co-Founder Arab Policy Institute “Tunisian Think Tank” Tunisia.  Headed the Al Jawhara Medical Research Institute Strategic Committee.  Member of King Abdullah Medical City project steering Committee.  Co-Founder and Overseas’ President of MEGA , the Middle East Geneticists Association, USA

4 - Employment History:

Dates: September 2009 to date: Arabian Gulf University, Manama, Bahrain Dean College of Graduates studies Professor and Chairman of the Biotechnology Program King Fahd Chair of Medical Biotechnology

Major achievements: managerial & Academic

MANAGERIAL:  Contribution to the development of two of the university quinquennial strategic plans.  Restructuring of the College of graduate studies through the development and implementation of a new organization that improved administrative functions.  Development of new policies and Streamlining with the university strategic objectives.  Contributed to the university, institutional accreditation from NCAAA.  Development of a new strategy for scientific research that yielded a 200% increase of international scientific publications and 300 % of IP production  Introduction of novel education technologies at the college class room (Black board, moodles, blended learning)  Improvement the college international visibility through the organization of international scientific events[conferences, workshops, seminars, scientific journal “ The Arabian Gulf Journal for Scientific Research)

 Increase of the international collaboration with world-class universities and research

organizations. 2

Page

ACADEMIC

 Review and revision of all the programs curricula (17) according to international criteria.  Development and Launching of a PhD program in Biotechnology [Health & Environment]  Development and Launching of a PhD program in Innovation Management.  Development of a graduate level program in Bioinformatics.  Production of the first genetically modified transgenic animal (Mouse) in an Arab research and education institution by my research group at AGU. (Patent Pending)  Development of monoclonal antibodies for cancer treatment engineered to fit the genetic background of patients by my research group at AGU. (Patent Pending).  Development by genetic engineering of a novel biological agent for the treatment of inflammation by my research group at AGU. (Patent Pending)  Development of generic improved form of the biodrugs : Interferon Gamma and Interferon alpha by my research group at AGU. (Patent Pending)  Trained/Supervised 9 PhD and 15 Master students

Dates: September 2008-August 2009: Sabbatical year

King Saud University, Ryadh, Saudi Arabia Visiting Professor /College of Pharmacy Senior Advisor Strategy, KSU Transfer of Technology Office and Riyadh Techno Valley/ KSU President Office

Dates: May 2004-August 2008:

JeddahBiocity Inc (A biotechnology Holding Group) Location: Jeddah,KSA Position: Group Chief Scientific Officer CEO RethAb Branch: General Manager JBC is a leading biotech holding company. Its business is to screen for technically advanced biotech businesses, transfer of Technology, invest in existing companies and/or create and foster biotech companies, offer them to the market for equity investment and collect premium on the benefit. The company annual turnover was around 200 million SR

Major achievements: Biotech Business Acquisition, Joint venture & Technology Transfer  I have selected, evaluated and transferred the technology from “GeneWay” a San Diego, California-US biotech company in which JBC invested 4 M US $.  I have developed two other biotech companies. Namely “Arabio”[100M $ investment] which is the first vaccine manufacturing company in the Middle East and BioScan [75 M$ SR Investment] the first private company specialized in advanced medical imaging for early diagnostic of cancer in KSA. JBC collected a substantial premium upon inviting equity investors in these two companies  I have carried out the feasibility studies and promotion of two science parks projects [Jeddah & Medina].  I have founded “RethAb” a JBC startup company specialized in the development of Antibodies.[18 M$ SR investment] and acted as its CEO 3

Page

Dates July 93-April 2004

Institute Pasteur/University Tunis Al Manar/ Location: Tunis

Position: Senior Scientist/Group Leader Professor of Molecular Biotechnology

The Pasteur Institute is a semi public/Private centennial institution affiliated with to the University of Tunis AL Manar. Its main business is to provide health care services mainly through vaccines manufacturing and supply and to carry out health products & services research and development along with academic training.

Major Achievements: academic, scientific research & management

 Teaching &Training

 Taught Molecular Biology, Molecular Genetics, Immunology, Biotechnology, and Cell Biology to Graduates Life sciences and biomedical sciences students.  Trained/Supervised 18 PhD and 35 Master students 2 medical doctors’ thesis and graduated 15 Engineers in Biotechnology& Medical Sciences.

 Research &Development & Technology Transfer

 Development/invention of five health care products & filled for five international discovery patents USA & Europe:

1. Two clones and a full process for the production of recombinant human interferon alpha in Pichia pastoris: EPO [European Patent Organization] 2. A strategy to produce soluble recombinant human interferon alpha in E.Coli: USPTO [United State Patent Trade Organization] 3. Selegrin: A novel Chimeric, genetically engineered adhesion molecule with anti-inflammatory potential; [EPO] 4. A novel antibody to the pro inflammatory leukocyte adhesion molecule CR3: [USPTO] 5. Method for preparing recombinant mycobacterial polypeptides in yeast and their use in diagnostic of mycobacterial related diseases: [USPTO]

 Established strategic business alliances with world top pharmaceutical companies and transferred the technology for an anti-inflammatory monoclonal antibody [Serono International, Switzerland], and a serology kit for the diagnostic of tuberculosis [ Biorad International USA]  Raised and managed up to 2.5M US $ of grants for biotech-products development.  Established Tunisia first national service of DNA-based paternity testing and realized a CAGR of 46%. Transferred the technology to four new companies.  Co-Founded “Cylyx” a biotech startup company in the biopharmaceutical Field.

 Built worldwide collaborative network for biotech development. 4

Page

Dates: 1985 - 1993

Harvard University/Mass General Hospital Location: Boston -USA

Position: April 85-June 1989 Postdoctoral fellow Children Hospital/Harvard Medical School

July1989-September 1993: Senior Scientist: Massachusetts General Hospital/Harvard Medical school

MGH is a Harvard University Medical, Research and training center. My assignment was a research & development scientist at the Navy Yard research facility that was dedicated to the development of startup companies specialized in medical biotechnology.

Major Achievements: academic, scientific research & management

 Raised and managed up to 4 M US $ of grants for biotech-products development  Development of new health care products and procedures for which I was granted international discovery patents  Founded “MEGA” The middle East Geneticists Association of America  Trained and supervised students & staff.

4-Transfer of technology Activity: From 1998 to date:  Strategic and Technology transfer advisor to several international Pharmaceutical companies.[PSI, SAJA, MEDIS, WestPharma,Biocare,UniMed…]  Strategic & Technology transfer advisor and member of the scientific board of the Tunisian Health BioPArk “Sidi Thabet”.  Biotech advisor for the Tunisian Institute of Strategic Studies: Carried out the biotech strategic part for the project entitled “Tunisia 2030”  Business & Transfer of technology Advisor for “Phykoytek” a US biotech company [Austin, Texas, USA] Leader in Biofuel development  Business & Transfer of Technology Advisor for “ BI++” a Swiss IT company [Gland], leader in business performance software’s.  Consultant in Biotechnology for the International Development and Research Center, Montreal, Canada [IDRC].

5

Page

5 - Education :

INSTITUTION AND LOCATION DEGREE YEAR FIELD OF STUDY

Certification for Strategic Global Innovation Institute, Chicago, Il , USA 2016 Management Innovation Expert Robert Kennedy School of Business, Zurich, Switzerland e-MBA 2005 Management

Habilitation [State Doctorate in Biological Sciences & Biotechnology Academy of Tunisia, Institute Pasteur , Tunis Biological Sciences] Tenure Track 1999

Review

1986- Harvard University , Medical School, Boston , USA Post doctoral training Molecular Biology & Biotechnology 1993 University of Tunis Al Manar & [Harvard University, Boston, USA] PhD [w/ honours] 1994 Molecular Genetics

University Paul Sabatier, Toulouse, France in Association with the University of Oxford, UK) PhD [w/ honours] 1985 Molecular Biology

Diploma of Pasteur Institute, Paris Microbial Immunology [w/ 1982 Basic & Clinical microbial Immunology honours]

MSc : Master Immunology [w/ University Paul Sabatier, Toulouse, France 1982 Molecular Immunology honours]

Certificate of Speciality in “ “ “ 1981 Basic & Clinical Immunology Immunology [w/ honours]

“ “ “ MSc : Master in Biological 1980 Molecular Genetics Sciences [w/ honours]

“ “ “ Bachelor Biological science 1978 Biological sciences & Molecular Biology

6 –Transfer of Technology Specific Skills, Mastered:  Biotech Road Mapping & Benchmarking.

 Intellectual Property strategies 6  Private Placement Memorandum and Business Plan writing.

Page

 Setting up of strategic health biotech alliances and partnerships through joint ventures  Due diligence on all biotech businesses.  Expertise in Biopharmaceuticals : Biosimilars  Science Parks setting up & Development

7- Honors

. Laureate of the EMBO, European Molecular Biology Doctoral award: 1982 . Laureate of the American Arthritis Foundation Postdoctoral Fellowship:1986 . AUPELF-UREF (Francophony Agency) Montreal-Canada, Research Excellence Award1994. . Prize of Excellence in Molecular Genetics, The Royal Academy of Science, . Elected member of the Scientific Council at the Institute Pasteur of Tunis. 1997-2002 . Member of the editorial board and reviewer in several biotech Journals [Journal of biotechnology, Biotechnology Progress, Cytotechnology, Enzyme & Microbial technology, In Silico Biology,, Annals of the Institute Pasteur……] 1990 to date . Award for the best innovative project, Global Innovation Institute Chicago Ilinois, USA&LEAD institute Dubai UAE, Innovation Boot Camp May 2016.

8- Selected Peer-Reviewed Publications.

 Cambon-Thomsen, A., Blancher, A., Clement, D., Fathallah, D. and Thomsen, M. (1984). Comparison of human-human and human-mouse hybridoma systems for the production of alloreactive human monoclonal antibodies. Histocompatibility testing, ed. E.D. Albert, et al. Springer Verlag, Berlin Heildelberg, pp. 444.

 Abbal, M. , Thomsen, M., Cambon-Thomsen, A., Archambeau, J., Calot, M. and Fathallah, D. (1985). Two subtypes of BFF by isoelectrofocusing : differential linkage to other HLA markers. Human Genetics. 69: 181-183.

 Fathallah, D., Abbal, M., Thomsen, M., Cambon-Thomsen, A. and Campbell, R.D (1985). A DNA restriction fragment length polymorphism in the complement region of the human MHC shows an absolute correlation with polymorphism of complement factor B (BF) defined by isoelectrofocusing. J. ImmunoGenet. 12: 321-326.

7

Page

 Fathallah, D., Isenman, D.E. and Carroll, M.C. (1987). Structure-function studies on complement protein C4 using site directed mutagenesis. Journal of Cellular Biochemistry. IIC, Alarn R. Liss, Inc., New York.

 M.C. Carroll, M.D. Fathallah, L Bergamaschini, E.M. Alicot & D.E. Isenman (1989).The chemical basis for the functional hemolytic difference between the two isotypes of human C4. Faseb Journal V6, n°3, 542-47.

 Fathallah M.D., Dana N. and Arnaout M.A. (1990) Mapping of mAb-defined epitopes in the leukocyte beta2 integrin CD 11b to the unique A-domain. J. Clin. Resch. V 38, 4-7

 Carroll M.C., Fathallah D.. , Bergamaschini L., Isenman D. (1990) Substitution of a single amino acid (aspartic acid for histidine) converts the functional activity of human complement C48Bto C4A. Proc. Nat. Ac. Sc. (USA) 87 ; 6868-6872

 Arnaout M.A., Dana N., Simmons D. & Fathallah D.. (1990). Two point mutation in the leukocyte CD18 gene in a patient with CD11/CD18 deficiency J. Clin. Inves. 85; 977-980.

 Dana N., Fathallah D. , and Arnaout M.A. (1991) Expression of a soluble and functional form of the human Beta2 integrins CD11b/CD18. Proc. Nat. Ac. Sc. (USA) 88, 3106-3110

 Fathallah D.., Cherif D.,Dellagi K. and Arnaout M.A. (1993) Molecular cloning of a novel HSP-70 gene from a mutant B cell line. Journal of Immunology 151, 813-815

 Fathallah D.M. Bejaoui M., Dellagi K. & Sly W. (1993) A single splice junction mutation underlies the carbonic anhydrase II deficiency in patients of arab descent. Faseb Journal V9, 2, 98

 Fathallah D., Bejaoui M. , Sly W. Lakhoua R. & Dellagi K.(1994) A unique mutation underlying the carbonic anhydrase II deficiency syndrome in patients of arab descent. Human Genetics : 94 : 581-584

 Nava D., Fathallah D.., Arnaout M.A. & (1994). Role of the beta 2 integrins in leukocyte adhesion: cells adhesion molecules II. Integrins: The Biological Problems. CRC Press; Yoshikazu Takada.

 D.M.Fathallah M.Bejaoui, K.Ouahchi, W.S. Sly & K.Dellagi (1996). Evaluation of mental retardation in carbonic anhydrase II deficients patients from southern Tunisia. Am. J. Hum Genet, Vol 59, n°4,2165 8

Page

 D.M.Fathallah, K. Zerria, R. Barbouche & K.Dellagi (1996) ß-Propiolactone alters gene expression and could guarantee the safety of inactivated vaccines produced on continous cell lines. Am. J. Hum Genet, Vol 59, n°4, 2135

 Fathallah D., Bejaoui M., Chater K. , Sly W.S. & Dellagi K. (1997). Genetic analysis in Carbonic anhydrase II (CA II) deficient Maghrebian patients: Evidence for founder effect and presence of a hot spot recombination in the CA II locus. Human Genetics 99: 634-637.

 D.M. Fathallah, T. Jamal, R. Barbouche, M. Ben Hariz & K. Dellagi (1997): Mechanistic model for mutations causing Leukocytes Adhesion Deficiency: Role of the local nucleotide sequence. Medizinische Genetik Vol 9 n°2 p150

 Fathallah D., Dellagi K , M. Qumsiyeh & Teebi A. (1998) Molecular genetics of the Maghreb and the middle east populations. American Journal of Medical Genetics 78: 90-91

 Fathallah D., Zerria K., Barbouche R.,& Dellagi K.(1999) A Model to Study the Effects of a viral inactivator (ß-Propiolactone) on DNA ligation and gene expression in E.Coli and Cos cells.Vaccine17, 95-98

 T.Jamal,R.Barbouche,M. Ben Hariz, K.Dellagi and Fathallah D. (1998) Genetic and Immunological assessment of a bone Marrow transplantation in a patient with a primary immune deficiency : Leukocytes adhesion deficiency . Archives Institut Pasteur, 75(3-4):177-83.

 Fathallah D., T Jamal, R. Barbouche, M. Bejaoui, M. Ben Hariz& Dellagi K (2001) Two Novel Frame Shift, Recurrent and De Novo Mutations in the ITGB2 (CD18) Gene Causing Leukocyte Adhesion Deficiency in a Highly Inbred North African Population.. J Biomed Biotechnology 1(3):114-121.

 H Kallel, H.Zaïri, S. Rourou , M. Essafi, M. Barbouche, K. Dellagi &. Fathallah D. (2002) Optimization of a hybridoma cell line Growth and Antibody production in a spinner flask using a Taguchi Experimental Design. Cytotechnology, 39:9-14

 A.Bobba, E. Marra, D.M. Fathallah & S. Giannattasio (2003) Non radioactive detection of five common microsatellite markers for ATP7B gene in Wilson disease patients. Mol Cell Probes. 2003 Dec;17(6):271-4.

 H. Kallel and D. M. Fathallah (2003) A process to produce an anti 2 integrin monoclonal antibody by a hybridoma cell line grown in a 2-liter stirred tank bioreactor. Bioprocess International V.1 No 12, 54-60.

 Zerria K., K. Dellagi & Fathallah D.M. (2003) Cloning of the rat CR3 9 alphaM (CD11b) subunit, expression and binding assay of recombinant

Page

isolated CD11b VA (A-domain) and ICAM-1 Ig modules. Arch Inst Pasteur Tunis. 2002;79 (1-4):11-7.

 Imen Rabhi, Naouel Guedel, Imen Chouk, Khaled Zerria , Koussay Dellagi & Dahmani M. Fathallah. (2004) A Novel simple and rapid PCR-based site directed mutagenesis method. Mol. Biotechnology. 26(1):27-34.

 Arredi B, Poloni ES, Paracchini S, Zerjal T, Fathallah DM, Makrelouf M, Pascali VL, Novelletto A, Tyler-Smith C.A (200 4) Predominantly neolithic origin for Y-chromosomal DNA variation in North Africa. Am. J. Hum. Genet. Aug; 75(2):338-45

 Ajroud K, Sugimori T, Goldmann WH, Fathallah DM, Xiong JP, Arnaout MA (2004) Binding Affinity of Metal Ions to the CD11b A-domain Is Regulated by Integrin Activation and Ligands. J Biol. Chem. 11; 279(24):25483-8.

 Guedel-Ben Tanfous N., Kallel H.. Jarboui M. A Fathallah D. M.(2005) Expression in Pichia pastoris of a recombinant scFv form of MAb 107, an anti human CD11b integrin antibody. Enz. Micro. Tech. Vol 38 (5): 636- 642

 Tlili , M. Ali Jarboui, A. Abdelghani,*, D.M. Fathallah, M.A. Maaref (2005) A novel silicon nitride biosensor for specific antibody–antigen interaction. Materials Sciences & Engineering C25,490-495

 Halioui-Louhaichi S, Ben Hariz M, Fathallah Dahmani M, Barbouch MR, Mahmoudi J, Bejaoui M, Fischer A, Dellagi K, Ben Ammar B, Maherzi A. Deficient expression of leukocyte adhesion proteins. A new Tunisian case. Tun Med. 84(7):464-6

 K. Zerria, E. Jerbi, S. Hammami , S. Boubaker, J.P. Xiong, , M.A. Arnaout§ & D. M. Fathallah (2006) Recombinant CR3 A domain Protects Against Skeletal Muscle Inflammatory Injury in Rat. Immunology 119,431-440.

 C. Benabdesselem, D. M. Fathallah, R. C. Huard, Hongxia Zhu, M. A. Jarboui, K. Dellagi, John L. Ho, and Ridha M. Barbouche (2006) Enhanced patient serum immunoreactivity to recombinant Mycobacterium tuberculosis CFP32 produced in the yeast Pichia pastoris: Potential for the serodiagnosis of tuberculosis. Journal Clinical Microbiology 44(9):3086-93.

 C. Benabdesselem M.R. Barbouche, M.A. Jarboui, J. L. Ho, K. Dellagi and

D. M. Fathallah (2007) Expression in Pichia pastoris, purification and characterisation of recombinant Mycobacterium tuberculosis culture filtrate protein CFP32. Mol Biotechnol. 35(1):41-50.. 10

Page

 D. Zouari Ayadi, H. Chouayekh, S.Mhiri, K. Zerria, D. M. Fathallah, and S. Bejar (2007): Expression and efficient secretion of the  integrin CD11b A- domain from Streptomyces lividans. Journal Biomedicines & Biotechnology 07 (1) 54,237-44

 I.Rabhi-Essafi, A. Sadok, N. Khalaf , and D. M. Fathallah (2007) A strategy for high level expression of soluble and functional human Interferon  as a GST-fusion protein in E. coli . Protein Expression, Design & Selection. 20(5):201-9

 N. Guedel-Ben Tanfous, B. Larguech , M. Essafi, Ridha Barbouche D. M. Fathallah (2007) Characterization of a novel monoclonal antibody with restricted specificity to the free Integrin M [CD11b] subunit. Hybridoma 26(6):373-9

 I.Rabhi-Essafi and D.M. Fathallah (2011) Enhanced Biological Activity of Recombinant Human Interferon Alpha Produced in Pichia pastoris using a codon-optimized synthetic cDNA. International Journal Biochemistry and Biotechnology Volume 7 Number 4, pp. 463-480.

 B. Selim, M. Salem-Bekhit, M. Zghal, Y. Jamous, F. Al-Anazi , I Al Sarra, M. Bayomi and M.D. Fathallah (2012). Introducing Plasmid DNA Fingerprinting in the Quality Control of pDNA Vaccine. International Journal of Biotechnology and Biochemistry 8, No 2 (2012) pp. 87-100.

 B. Salim, S. Bourguiba-Hachemi, M.Zghal, I.Rabhi and M.D. Fathallah (2012). An Integrative Gene Optimization Method for the Design of Recombinant Protein Drugs and DNA Vaccines. (In Press). International Journal Biotechnology& Bioscience

 Safa Taha, M. Dahmani Fathallah • Moiz Bakhiet (2014) An interspecies conserved motif of the mouse immune system-released activating agent (ISRAA) induces proliferative effects on human cells. Molecular medicine Reports (10) 75-81 (IF:1.554)

 Sahar Elhannan • Safa Taha • Noureddine Ben Khalaf • Halla Bakheit • M Dahmani Fathallah • Moiz Bakhiet (2015) Induction of dissociated cytokine profiles by ISRAA with selective critical involvement of ERK1/2 in its signaling functions. International Journal of Molecular Medicine 36(6).(IF 2.088)

 Sonia Bourguiba-Hachemi and M. Dahmani Fathallah. DNA testing of meat foods raises issues beyond adulteration. Sky Journal of Food Science 2016 January, Vol. 5(1), pp. 001 – 007 (Available online http://www.skyjournals.org/SJFS) 11

Page

 Dana Ashoor, Sonia Bourguiba-Hachemi, Maryam H. A. Marzouq, M.Dahmani Fathallah. (2016) Production of genetically engineered low- affinity human Immunoglobulin receptors FcγRIIa (CD32a) and FcγRIIIa (CD16a) extracellular domains in Pichia pastoris. International Advanced Research Journal in Science, Engineering and Technology, February Vol. 3, Issue 2, ISSN (Online) 2393-8021). (IF: 3.943)

 Raed H. Qaddourah, Sonia Bourguiba-Hachemi, Maryam Marzouq, Abdel Halim Salem, Hamdi Jarjanazi, Miral Mashhour, Wassim F. Raslan, and M. Dahmani Fathallah. High risk for lung and bladder cancers in the Arabian Gulf population associated with EGFR genetic variants regulating expression. International Journal of Current Research 2016, April Vol. 8, Issue, 04, pp. 29728-29734. (IF: 6.226)

 Mounir M Salem-Bekhit1,2, Mohamed Osman Gad El Rab, Mahmoud M Tawfick, Mohammad Raish, M. Dahmani Fathallah (2016) Humoral and cellular immune responses to modified hepatitis B plasmid DNA vaccine in mice. Tropical Journal of Pharmaceutical Research 15 (4): 687-693. (IF 4.22)

 N. Ben Khalaf, S. Taha, M. Bakhiet, M.Dahmani Fathallah (2016) A Central Nervous System activation-dependent Intron embedded gene encodes for a novel mouse Fyn binding protein. PLOS 1 (11) 2 (IF 3.234)

 Sonia Bourguiba-Hachemi, Tebah K. Ashkanani, Fatema J. Kadhem, Wassim Y. Almawi, Raed Alroughani, M. Dahmani Fathallah (2016). ZFAT gene variants association with Multiple Sclerosis in the Arabian Gulf population: A genetic basis for gender-related susceptibility. Molecular Medicine Reports.

 M. Dahmani Fathallah (2017) A New Integrative Model to Train the Next Generation of Biomedical Scientists. Adv Biotech & Micro. V7,1.

 M. Dahmani Fathallah (2017) Genomics, Gene Editing and Biologics: The Bolsters of the New Medical Paradigm Curr Trends Biomedical Eng & Biosci. DOI: 10.19080/CTBEB.2017.06.555694

 H. Ouadani, I. Ben-Mustapha, M. Ben-ali, B. Larguèche, T. jovanic, S. garcia, B.Arcangioli, H. Elloumi-zghal, M.D. Fathallah, M. Hachicha, H.Masmoudi, F. Rougeon, M.R.Barbouche (2016). Activation induced cytidine deaminase mutant (aid-his130pro) from hyper igm 2 patient retained mutagenic activity on shm artificial substrate. Mol Immunol 4; 79:77-82.

 Huda al Sayed ahmed, Wasim fawzi Raslan, Abdel halim Salem Deifalla3 and Mohamed Dahmani Fathallah (2018). CD163 is a predictive biomarker 12

Page

for prognosis of classical Hodgkin's lymphoma in Saudi patients. Molecular and Clinical Oncology. DOI: 10.3892/mco.2019.1850

 Hashem A. Almusawi, Aisha Al Foderi, Fatma Al Saad, Mohammed AAl Mannai and M.Dahmani Fathallah (2018).Consensual Cooperative-Learning: A New Method to Harmonize the Learning of Complex Knowledge. American Journal of Educational Research 6 (12):1710-1714.

 Huda al Sayed ahmed, Wasim fawzi Raslan, Abdel halim Salem Deifalla3 and Mohamed Dahmani Fathallah (2018). Overall survival of classical Hodgkin's lymphoma in Saudi patients is affected by XPG repair gene polymorphism.Biomedical Reports. DOI: 10.3892/br.2018.1165.

 Noureddine Ben Khalaf, M. Dahmani Fathallah (2018) Protein Disulfide Isomerase: A New Class of Drug Target. Curr Trends Biomedical Eng & Biosci 12 (3): CTBEB.MS.ID.555838 (2018

 Dana N. Ashoor, Noureddine Ben Khalaf, Sonia Bourguiba-Hachemi, M. Dahmani Fathallah (2018). Engineering of the upper hinge region of human IgG1 Fc enhances the binding affinity to FcγIIIa (CD16a) receptor isoform. Protein Engineering Design and Selection 31(6). DOI: 10.1093/protein/gzy019

 Noureddine Ben KhalafWedad Al-Mashoor Azhar Saeed[...]Mohamed Dahmani Fathallah (2019) The mouse intron-nested gene, Israa, is expressed in the lymphoid organs and involved in T-cell activation and signaling. Molecular Immunology. May 2019

 Chaouki Benabdessalem, Houcemeddine Othman, Rym Ouni, Mohamed Dahmani Fathallah (2019) N-glycosylation and homodimeric folding significantly enhance the immunoreactivity of Mycobacterium tuberculosis virulence factor CFP32 when produced in the yeast Pichia pastoris. Biochemical and Biophysical Research Communications June 2019

9- Research Funding.

1. 1986-1992 American national Institute of Health, American Arthritis foundation & American March of Dimes foundation: Analysis of the structure-function of leukocytes adhesion molecules and their role in inflammation.

2. 1992-1996: Tunisian Association for Myopathy: Project:

Investigation of the Molecular Genetic Basis of Osteopetrosis a common Genetic disease in the Arab population. M. D. Fathallah P.I. 13

Page

3. 1994-1997: European Community: Avicenna Program: Project: Development of the technical tools for investigation and diagnosis of genetically transmitted diseases & investigation of the psycho-social perception and prevention approaches of genetic diseases. M. D. Fathallah P.I.

4. 1994-1998: International Centre of Genetic Engineering and Biotechnology, Trieste, Italy: Project: Development of novel molecular approaches for the development of anti inflammatory agents. M. D. Fathallah P.I.

5. 1998-2001: Institut Pasteur de Tunis Research Funds: Project: Development of novel expression systems for the production of recombinant proteins of medical interest (Pichia pastoris , streptomyces lividans and insect cells): M. D. Fathallah P.I.

6. 2000-2004: Institut Pasteur de Tunis / Biotechnology Action: Development of a full process for the production of a pharmaceutical grade recombinant human interferon . M. D. Fathallah P.I.

7. 2001-2005: Serono international in collaboration with Massachusetts General Hospital, Boston USA. Project: Engineering and structure function analysis of recombinant forms an anti human CD11b monoclonal antibody. M D. Fathallah P.I.

8. 2003-2004: Serono International: Project: Assessment of anti CD11b mAb 107, anti-inflammatory therapeutic potential in a primate model [Maccaca fascicularis] of hemorrhagic shock [Preclinical study] M.D. Fathallah P.I.

9. 2004 to 2006 WHO/TDR: Assessment of novels antigens for the serodiagnostic of tuberculosis M.D. Fathallah Co-investigator.

10. 2005 to 2007 National Institute of Health, USA. Novel Diagnosis Methods: CFP32-based Point-of-Care Diagnosis of Tuberculosis research and development. M.D. Fathallah Co investigator

11. 2007 to 2011: Biorad International: Evaluation of Mycobacteria CFP32 recombinant antigen for the serodiagnostic of Tuberculosis on the WHO world battery of TB patient’s sera. M D Fathallah / P I

12. 2012 to 2015: Kuwait Foundation for the Advancement of Science. Human DNA profiling using STR and SNP genomic markers: A comparative study in the Kuwaiti population M D Fathallah / P I.

13. 2014-2017: Kuwait Foundation for the Advancement of Science.

14 Techno-Economical Evaluation of the Production of Bio Drugs; Study of

Page

two processes for the manufacturing of recombinant Human Interferon Alpha.

10. Collaboration Network

 Harvard Medical School , Massachusetts General Hospital, Boston, MA- USA  Harvard Medical School Children’s Hospital, Boston, MA-USA  Boston College Business School, MA-USA  Global Leadership Institute, Boston, MA-USA  Global Innovation Institute, Chicago, Il-USA  Cornell University Medical School, New York, NY-USA.  Missouri State University, USA  Institute Pasteur, Paris, France.  University of Mainz Medical School, Germany  University of Salzburg, Salzburg, Austria  Immunology Institute, La Havana, Cuba  University of California Los Angeles [UCLA] Medical School, CA-USA  Yale University , Medical school, New Haven Connecticut-USA  Institute of Metabolic Disease, Bari, Italy  CEPH : Genome centre Paris, France  University of Melbourne, Medical School, Australia  Cataluna Science Parks, Barcelona, Spain  Biorad BioPharmaceutical  Serono BioPharmaceutical

11. Others:

 Invited lecturer: Several International universities: USA, France, Algeria, Bahrain, Kingdom Saudi Arabia, Mexico, Pakistan, Morocco, Egypt  Guest speaker at United Nation institutions: UNIDO, UNDP, ESCWA, ALECSO.  Three published books: . How to write & Publish a Scientific article, IPT Eds , Tunis, 1996 . Safety issues for the laboratory use of Radionucleotides, Character Eds Tunis 1998

. Transfer of Biotechnologies in the Medical and Pharmaceutical

Fields KSU Eds Ryadh, 2009 15

Page

 Book in preparation : Biotechnology & Health Issues : The 21th Century Medical Challenge  Over 100 lecture worldwide at Seminars and Scientific Conferences  Members of 12 International scientific Societies.  Writing of general information articles on Biotech, Higher Education strategies &Foresight  Organized international scientific meetings [#8] and Biotech workshop and courses [#15].  Speak and write equally English, French and Arabic.  Personal activities: Music (Opera), Sports (Golf, Tennis and football), Literature (History, Sociology, Poetry, philosophy). Arabic Calligraphy

16

Page